Related Experiment Video
Updated: Jun 28, 2025
In vitro Assessment of Myocardial Protection following Hypothermia-Preconditioning in a Human Cardiac Myocytes Model
Published on: October 27, 2020
Immediate Platelet Inhibition Strategy for Comatose Out-of-Hospital Cardiac Arrest Survivors Undergoing Percutaneous
Peter Kordis1,2, Jernej Berden1,2, Ursa Mikuz1,2
1Center for Intensive Internal Medicine, University Medical Center Ljubljana, 1000 Ljubljana, Slovenia.
Insights
Periprocedural cangrelor effectively bridged the P2Y12 inhibition gap in out-of-hospital cardiac arrest survivors undergoing PCI and TTM. This pilot study demonstrated safe and immediate platelet inhibition without significant drug interactions.
Area of Science:
- Cardiology
- Pharmacology
- Intensive Care Medicine
Background:
- Comatose survivors of out-of-hospital cardiac arrest (OHCA) undergoing percutaneous coronary intervention (PCI) and target temperature management (TTM) face high stent thrombosis (ST) risk.
- Delayed P2Y12 platelet inhibition, even with potent agents, contributes to this risk, creating a critical therapeutic window.
- A periprocedural strategy is needed to rapidly achieve adequate platelet inhibition.
Purpose of the Study:
- To evaluate the efficacy of periprocedural cangrelor in achieving immediate platelet inhibition in OHCA patients undergoing PCI and TTM.
- To assess the safety and potential drug-drug interactions between cangrelor and enteral ticagrelor.
- To bridge the 'P2Y12 inhibition gap' and potentially reduce stent thrombosis risk.
Main Methods:
- A pilot randomized study involving 30 comatose OHCA patients undergoing PCI and TTM (32-34 °C).
- Patients received unfractionated heparin, aspirin, and enteral ticagrelor; the intervention group additionally received intravenous cangrelor.
- Platelet inhibition was assessed using VerifyNow® and Multiplate® ADP at multiple time points post-PCI.
Main Results:
- Cangrelor significantly reduced platelet reactivity at 1 and 3 hours post-PCI compared to the control group (VerifyNow®: p < 0.001; Multiplate® ADP: p < 0.001).
- The proportion of patients with high on-treatment platelet reactivity was significantly lower in the cangrelor group at 1 and 3 hours (p < 0.001 and p = 0.007, respectively).
- Bleeding events were similar between groups, and no significant drug-drug interaction with ticagrelor was observed.
Conclusions:
- Periprocedural cangrelor safely and effectively induces immediate and profound platelet inhibition in this high-risk patient population.
- Cangrelor appears to be a viable strategy to bridge the P2Y12 inhibition gap during PCI in OHCA survivors.
- The combination of cangrelor and enteral ticagrelor demonstrated a favorable safety profile with no significant interactions.
Abstract:
Background: Comatose survivors of out-of-hospital cardiac arrest (OHCA) undergoing percutaneous coronary intervention (PCI) and target temperature management (TTM) are at increased risk of stent thrombosis (ST), partly due to delayed platelet inhibition even with more potent P2Y12 agents. We hypothesized that periprocedural cangrelor would induce immediate platelet inhibition, bridging the "P2Y12 inhibition gap". Methods: In our pilot study, we randomized 30 comatose OHCA patients undergoing PCI and TTM (32-34 °C) into cangrelor and control groups. Both groups received unfractioned heparin, acetylsalicylic acid, and ticagrelor via enteral tube. The cangrelor group also received an intravenous bolus of cangrelor followed by a 4 h infusion. Platelet inhibition was measured using VerifyNow® and Multiplate® ADP at baseline and 1, 3, 5, and 8 h post PCI. Results: Patient characteristics did not differ between groups. VerifyNow® showed significantly decreased platelet reactivity with cangrelor at 1 h (30 vs. 221 PRU; p < 0.001) and 3 h (24 vs. 180 PRU; p < 0.001), with differences at 5 and 8 h. Similarly, the proportion of patients with high on-treatment platelet reactivity (HPR) in the cangrelor group was significantly lower at 1 h (0% vs. 67%; p < 0.001) and 3 h (0% vs. 47%; p = 0.007). Multiplate® ADP was also decreased at 1 h (14 vs. 48 U; p < 0.001) and 3 h (11 vs. 42 U; p = 0.001), with no difference at 5 and 8 h. The occurrence of bleeding events was similar in both groups. Conclusions: Cangrelor safely induced immediate and profound platelet inhibition. We observed no significant drug-drug interaction with ticagrelor.
Related Concept Videos
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...